1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Cancer Drug News 26 OCTOBER 2015

Cancer Drug News 26 OCTOBER 2015

  • October 2015
  • -
  • Espicom Business Intelligence
  • -
  • 12 pages

Industry Trend Analysis - Optimal Legacy/Innovation Balance To Maintain Roche's Growth Trajectory
Industry Brief - Spectrum Receives Evomela CRL From FDA
Industry Brief - Synta Terminates Ganetespib Phase III Trial In Lung Cancer
Industry Brief - Exelixis Initiates Cabozantinib Rolling NDA Submission For RCC In US
Industry Brief - Atara Bio's Activin Inhibitor Gains FDA ODD For OC
Industry Brief - MacroGenics/Merck Enter Immuno-Oncology Clinical Trial Collaboration
Industry Brief - Onivyde Approved In Taiwan For MPC
Industry Brief - Amgen Gains Positive CHMP Positive For Imlygic
Industry Brief - FDA Approves Yondelis For LPS/LMS
Industry Trend Analysis - Collaborative Approach Will Bolster AstraZeneca/Lilly's Immuno-Oncology Presence
Industry Brief - NW Bio Raises Funds To Advance DCVax-L/DCVax-Direct Programmes
Industry Trend Analysis - Greater Knowledge Application Boosting Cancer Vaccine Potential
Industry Brief - Nuevolution/Janssen Enter Drug Discovery Collaboration
Industry Brief - Symphogen Raises Funds To Advance Oncology Pipeline
Industry Trend Analysis - Novartis Maximising Chances Of Immuno-oncology Success
Industry Brief - Cancer Conferences - January 2016

Table Of Contents

Cancer Drug News 26 OCTOBER 2015

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Non-Small Cell Lung Cancer (NSCLC) - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Non-Small Cell Lung Cancer (NSCLC) - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • November 2016
  • by GlobalData

PharmaPoint: Non-Small Cell Lung Cancer (NSCLC) - Global Drug Forecast and Market Analysis to 2025 Summary Lung cancer is currently is the most common cause of death from cancer worldwide. Of total lung ...

Non-Small Cell Lung Cancer (NSCLC) - 5EU Drug Forecast and Market Analysis to 2025

Non-Small Cell Lung Cancer (NSCLC) - 5EU Drug Forecast and Market Analysis to 2025

  • $ 6995
  • Industry report
  • November 2016
  • by GlobalData

Non-Small Cell Lung Cancer (NSCLC) - 5EU Drug Forecast and Market Analysis to 2025 Summary Lung cancer is currently is the most common cause of death from cancer worldwide. Of total lung cancer incident ...

2017-2021 US Tumor Marker Testing Market: Emerging Opportunities and Growth Strategies for Suppliers

2017-2021 US Tumor Marker Testing Market: Emerging Opportunities and Growth Strategies for Suppliers

  • $ 6400
  • Industry report
  • February 2017
  • by Venture Planning Group

Complete report $9,800.  DataPack (test volumes, sales forecasts, supplier shares) $6,400. Highlights Comprehensive 620-page analysis of the US tumor marker testing market.Major issues pertaining to the ...


ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.